C&L: Bioxel CEO resigns

Bioxel Pharma has announced the resignation of Pascal Delmas as president and CEO. Bioxel also appointed Thomas Warden as vice-president, sales, marketing and regulatory affairs.

Denmark's Lundbeck has appointed Ulf Wiinberg its new chief executive officer.

Alfacell Corp. said its chief executive officer Kuslima Shogen will retire from the company by March 31, 2009.

Noven Pharmaceuticals has named former Pfizer senior executive Peter C. Brandt president and CEO.

Arpida announced that Dr Jürgen Raths will succeed Dr Khalid Islam as chief executive officer.

Cellectricon has named Jonas Ohlsson, the former chief of Mentice AB, as its new CEO.

Harvard Bioscience said Bryce Chicoyne has resigned as its chief financial officer, effective May 9.

Ablynx announced that Dr. Hennie Hoogenboom will be stepping down from his position as chief scientific officer and member of the executive committee. 

Hyperion Therapeutics has named Bruce F. Scharschmidt, MD as chief medical officer.

Labopharm has named Claire Brullé, M.D., senior vice-president and chief medical officer. 

Transdel Pharmaceuticals has appointed Paul Finnegan to the position of chief medical officer and COO. 

Hana Biosciences has appointed Anne Hagey, M.D. as vice president and chief medical officer.

Advaxis has hired Christine Chansky, MD, JD, FCLM, a veteran clinician, pharmaceutical industry medical director and FDA procedural specialist, to serve in the capacity of executive clinical officer.

Neuromed Pharmaceuticals has promoted Sean Cunliffe to chief commercial officer.

BR Pharma has appointed Adele Davis to the new position of head of clinical trials.

Sangamo BioSciences has nominated Thomas Wiggans to the company's board of directors.

Oragenics has named Dr. Marc Siegel and Kevin Sills to the company's board of directors.

Mel Rothberg has resigned from the board of Lotus Pharmaceuticals.

Metabasis Therapeutics has named Dr. Elizabeth Stoner to its board of directors.

Chemaphor announced that Jacques Brault was elected as a new member of Chemaphor's board of directors.

Aegera Therapeutics has named Jeremy Curnock Cook, executive chairman and founder of BioScience Managers Limited, and Gary Littlejohn, managing director of Desjardins Securities, to its board.

Shire said Thursday the dean of Tufts University's medical school, Michael Rosenblatt, has joined its board of directors.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.